BioPharm International May June 2026

Biopharma in 2026 advances decentralized manufacturing, AAV automation, QC modernization, and APAC clinical trial strategy.

Point-of-care manufacturing could expand personalized medicine by enabling faster, decentralized drug production, though quality and regulatory hurdles remain.

APAC clinical trials require tailored strategies to manage regulatory, operational, and cultural differences for efficient, high-quality study execution.

Advances in predictive modeling, translational bioanalytics, and human-relevant research systems may help reduce reliance on animal testing while improving the clinical relevance of preclinical drug development. Experts say these approaches could streamline IND preparation, lower costs, and support more informed decision-making across biopharmaceutical R&D.

Cell therapy QC bottlenecks stem from fragmented systems, for which scalable, automated ecosystems require systems-level redesign, digital integration, and mindset shift.

Automated density gradient ultracentrifugation boosts the efficiency of AAV purification.